The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

January 19, 2016 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Gajus/shutterstock.com

Image Credit: Gajus/shutterstock.com
Distinguishing between IPF and NSIP is the single biggest challenge in the interstitial lung disease world.

SAN FRANCISCO—“Interstitial lung disease is the last bastion of great medicine,” according to Paul Noble, MD, chair, Department of Medicine, director, Women’s Guild Lung Institute, Vera and Paul Guerin Distinguished Chair in Pulmonary Medicine, Cedars-Sinai Medical Center, Los Angeles. Making it great medicine, he said, are the many things still unknown about this disease.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
Explore This Issue
January 2016
Also By This Author
  • Antibodies Against Oxidized Phospholipids Protect Against Osteoporosis

In a presentation titled, The Changing Landscape in Fibrosing Lung Diseases, held at the 2015 ACR/ARHP Annual Meeting, Dr. Noble traversed the challenging terrain of accurate diagnosis of interstitial lung disease (ILD) given the multiple connective tissue disorders that may underlie ILD, such as scleroderma and rheumatoid arthritis (RA), as well as the many patients who fall into the gray area of undifferentiated connective tissue disease in which the disease has not yet fully revealed itself.

Dr. Noble

Dr. Noble

Dr. Noble focused his talk on the large gray area of undifferentiated connective tissue disease in which most patients with ILD fall and, in particular, on those patients with idiopathic interstitial pneumonia with autoimmune features.

Once connective tissue disease is excluded as an underlying cause of ILD, he said that an accurate diagnosis boils down to one of two conditions—idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP). Most patients (approximately 70%) will have IPF, and 15–25% will have NSIP.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Distinguishing between IPF and NSIP is the single biggest challenge in the interstitial lung disease world,” he said.

Driving the need to distinguish between IPF and NSIP is the drastic difference in prognosis between the two conditions, as well as advances in treatment that now permit more targeted treatment of disease. Rather than treating all patients with fibrosing lung disease with immunosuppression therapy, as was done in the past, he said that newer treatments now permit better treatment for patients based on the underlying cause of ILD. Most patients with IPF will succumb within five years without a lung transplant, according to Dr. Noble, who also said that new drugs slow disease progression but still don’t make the patient better.

Patients with NSIP rarely need a transplant, he said, and these patients have a better prognosis with immunosuppression therapy.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Noble’s presentation focused on IPF and NSIP, the how and why of distinguishing between them, as well as promising therapies emerging to treat IPF.

Distinguishing Between IPF & NSIP

Recognizing the different patterns of fibrosis between IPF and NSIP is critical to diagnosis and, even in the best of pathologists’ hands, is not easy, he said. He emphasized that definite IPF, in which honeycombing is evident on high-resolution computed tomography (HRCT), should not be biopsied, because that would do more harm than good.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: AC&R, American College of Rheumatology, conference, Diagnosis, fibrosing lung disease, pattern recognition, Research, rheumatologyIssue: January 2016

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.